摘要
目的探讨存活素si RNA表达质粒(mU6/survivin质粒)对化疗药物抑癌作用的影响。方法采用MTT法检测mU6/survivin质粒与多种常规肿瘤化疗药物对乳腺癌MCF-7细胞增殖的联合作用。结果比较单纯化疗药物作用组的各相应浓度点,si RNA表达质粒mU6/survivin与化疗药物顺铂、环磷酰胺、5-氟尿嘧啶或秋水仙碱合用组对肿瘤细胞MCF-7的细胞增殖抑制率均明显提高,差异均有统计学意义(P<0.01);对靶向DNA药物如顺铂、环磷酰胺和5-氟尿嘧啶的抗癌性能具有显著的协同增强作用(二者合用效应Q值均>1),但对靶向微管的药物秋水仙碱没有相加作用(Q值<1)。结论在解除肿瘤细胞中存活素功能的基础上进行药物化疗,可能是肿瘤治疗的一个新的可行方向。
Objective To study the influence of survivin siRNA expression plasmid on anti-tumor role of chemotherapeutic drugs. Methods The combined role of mU6/survivin plasmid and several chemotherapeutic drugs in the proliferation of MCF-7 cells was determined by MTT method. Results The combined use of mU6/survivin plasmid and cisplatin, cyclophosphamide, 5-fluorouracil or colchicine resulted in significant inhibition of MCF-7 cells com- pared with the single use of mU6/survivin plasmid or chemotherapeutic drugs （P 〈 0.01 ）. The synergistic effect was observed in the combination of pmU6/survivin and cisplatin, cyclophosphamide and 5-fluorouracil （Q 〉 1） other than colchicine （Q〈 1 ）. Conclusion The combination of chemotherapy and survivin deprival may be a novel regimen for cancer patients.
出处
《广东医学院学报》
2010年第1期4-7,10,共5页
Journal of Guangdong Medical College
基金
广东省中医药局科研课题(No.1050051)
